Cadonilimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Cadonilimab
- ak 104
- Ak-104
- AK-104
- ak104
- Ak104
- AK104
- AK104 (after the change)
- AK104 (before the change)
- AK104 (New Site)
- AK104 (Original Site)
- AK104 injection
- anti pd1 anti ctla4 bispecific antibody ak104
- ANTI-PD1/ANTI-CTLA4 BISPECIFIC ANTIBODY AK104
- cadonilimab
- Cadonilimab
- Cadonilimab (AK104)
- cadonilimab [INN]
- CADONILIMAB [USAN]
- Cadonilimab [WHO-DD]
- Cadonilimab Injection
- cadonilimab inn
- cadonilimab usan
- cadonilimab who dd
- Cadonilimab（AK104）
- Candonilimab (AK104)
And 6 more, listed on the interactive page.
- CAS registry numbers
- 2394841-59-7
- ChEMBL ID
- CHEMBL4594456
- FDA ingredient codes (UNII)
- 6FYG1DS4NW
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- cadonilimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- cytotoxic T-lymphocyte-associated protein 4 (CD152)
- Gene symbol
- CTLA4
- Protein identifier
- P16410
- Median affinity
- 10.1
- Affinity units
- pEC50
- Primary target
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- programmed cell death 1 (CD279)
- Gene symbol
- PDCD1
- Protein identifier
- Q15116
- Median affinity
- 10.29
- Affinity units
- pEC50
- Primary target
- Yes
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
- Action type
- Inhibitor
- Target
- Cytotoxic T-lymphocyte protein 4
- Protein identifier
- P16410
- Mechanism
- Programmed cell death protein 1 inhibitor
- Action type
- Inhibitor
- Target
- Programmed cell death protein 1
- Protein identifier
- Q15116
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
- Action type
- Inhibitor
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Programmed cell death protein 1 inhibitor
- Action type
- Inhibitor
- Target
- Programmed cell death protein 1
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Glioblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Mesothelioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001061
- Subject identifier
- D002583
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001416
- Subject identifier
- D002583
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Nasopharyngeal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004252
- Subject identifier
- D009303
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008528
- Subject identifier
- D001749
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001951
- Subject identifier
- D015179
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001961
- Subject identifier
- D018281
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001968
- Subject identifier
- D012509
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Vulvar Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001528
- Subject identifier
- D014846
And 12 more, listed on the interactive page.
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000211
- Condition identifier
- EFO_0000349
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000588
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001061
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001416
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002916
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004252
- Condition identifier
- EFO_0005221
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005708
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008528
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000485
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001012
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001951
- Highest recorded phase
- 2
And 55 more, listed on the interactive page.
- Event
- alanine aminotransferase increased
- Reports
- 3
- Reporting signal score
- 9.76484
- Event
- aspartate aminotransferase increased
- Reports
- 3
- Reporting signal score
- 10.1147
- Event
- hypoalbuminaemia
- Reports
- 2
- Reporting signal score
- 10.0585
- Event
- hypothyroidism
- Reports
- 2
- Reporting signal score
- 7.86108
- Event
- immune-mediated myocarditis
- Reports
- 2
- Reporting signal score
- 16.3001
- Event
- myelosuppression
- Reports
- 4
- Reporting signal score
- 21.8215
- Event
- white blood cell count decreased
- Reports
- 3
- Reporting signal score
- 8.94461
- NCT03261011
- NCT05235542
- NCT05868876
- NCT04172454
- NCT04349969
- NCT04547101
- NCT04572152
- NCT05021120
- NCT05142423
- NCT05559541
- NCT05644392
- NCT05915481
- NCT05944224
- NCT06327698
- NCT04220307
- NCT05587374
- NCT05790200
- NCT05898256
- NCT04380805
- NCT04868708
- NCT04982237
- NCT05227651
- NCT05817214
- NCT05824494
- NCT06209294
And 81 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 298 $ 298'''' $ 524 $ 524''''
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSQVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSAGGGGSGGGGSGGGGSGGGGSQAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVLR
- Component
- Glycosylation sites (N)
- Sequence
- 298 $ 298'' $ 524 $ 524''
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 145-201 $ 145''-201'' $ 221-214' $ 221''-214''' $ 227-227'' $ 230-230'' $ 262-322 $ 262''-322'' $ 368-426 $ 368''-426'' $ 490-564 $ 490''-564'' $ 512-705 $ 512''-705'' $ 625-293 $ 625''-693''
Related records
Trials (210)
- A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
- A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
- A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
- A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
- A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
- A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
- A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
- A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer
- A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
- A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
- A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
- A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours
- A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
In development for (44)
- Bile duct adenocarcinoma Phase 2
- Biliary tract cancer Phase 2
- Breast cancer Phase 2
- Cancer Phase 2
- Carcinoma of esophagus Phase 2
- Cervical adenocarcinoma Phase 3
- Cervical cancer Phase 3
- Cervical carcinoma Phase 3
- Cholangiocarcinoma Phase 2
- Clear cell renal carcinoma Phase 2
- Colorectal adenocarcinoma Phase 2
- Colorectal cancer Phase 2
- Colorectal carcinoma Phase 2
- Esophageal cancer Phase 2
- Esophageal squamous cell carcinoma Phase 2
- Exocrine pancreatic carcinoma Phase 2
- Gastric adenocarcinoma Phase 2
- Gastric cancer Phase 2
- Gastroesophageal junction adenocarcinoma Phase 3
- Glioblastoma Phase 1